CNS Pharmaceuticals (CNSP) News Today → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Free CNSP Stock Alerts $0.22 -0.01 (-4.41%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 1:07 PM | investorplace.comCNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q1 2024May 16 at 11:00 AM | finanznachrichten.deCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 13, 2024 | americanbankingnews.comCNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Up 35.1% in AprilApril 25, 2024 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) CEO to Present at LSX World Congress 2024April 4, 2024 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) Releases FY 2023 Financial Report, Corporate UpdateApril 3, 2024 | benzinga.comCNS Pharma Stock (NASDAQ:CNSP), Earnings Estimates, EPS, and RevenueApril 2, 2024 | investorplace.comCNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q4 2023March 20, 2024 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) Welcomes Proven Commercialization Leader to BoardFebruary 9, 2024 | investing.comCns Pharmaceuticals Inc (CNSP)February 3, 2024 | msn.comCNS Pharmaceuticals Launches Public Offering for Trial FundingJanuary 30, 2024 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) Releases Info on $4M Public Offering PricingJanuary 29, 2024 | finanznachrichten.deCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Pricing of $4.0 Million Public OfferingJanuary 29, 2024 | finance.yahoo.comCNS Pharmaceuticals Announces Pricing of $4.0 Million Public OfferingJanuary 19, 2024 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) Names Seasoned Biotech Leader to Board of DirectorsJanuary 18, 2024 | finanznachrichten.deCNS Pharmaceuticals, Inc.: Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of DirectorsJanuary 18, 2024 | finance.yahoo.comBiotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of DirectorsJanuary 17, 2024 | finance.yahoo.comCNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)January 6, 2024 | seekingalpha.comCNSP CNS Pharmaceuticals, Inc.December 18, 2023 | finance.yahoo.comCNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of BerubicinDecember 14, 2023 | morningstar.comCNS Pharmaceuticals Inc Ordinary SharesDecember 8, 2023 | msn.comCNS Pharmaceuticals files to sell 3.81M shares of common stockDecember 6, 2023 | finance.yahoo.comHow CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No CureNovember 22, 2023 | finance.yahoo.comCNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of EfficacyNovember 21, 2023 | msn.comCNS Pharmaceuticals files to sell 3.76M shares of common stock for holdersNovember 16, 2023 | finance.yahoo.comCNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug CandidateNovember 15, 2023 | finance.yahoo.comCNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year EndNovember 11, 2023 | morningstar.comCNS Pharmaceuticals Inc Ordinary Shares CNSPOctober 19, 2023 | finance.yahoo.comCNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO ConferenceOctober 17, 2023 | benzinga.comCNS Pharma Stock (NASDAQ:CNSP) Dividends: History, Yield and DatesOctober 16, 2023 | finance.yahoo.comGlioblastoma Is the Most Aggressive Type of Brain Cancer, With No Cure - CNS Pharmaceuticals’ Innovative Approach To Treatment Could Offer HopeOctober 13, 2023 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) Reports Rapid Pace of Enrollment in Berubicin StudyOctober 13, 2023 | benzinga.comGlioblastoma Is the Most Aggressive Type Of Brain Cancer, With No Cure – CNS Pharmaceuticals' Innovative Approach To Treatment Could Offer HopeOctober 11, 2023 | finance.yahoo.comCNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to DateSeptember 8, 2023 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) Looking Forward to Interim Results for Potentially Pivotal GBM StudySeptember 7, 2023 | finance.yahoo.comCNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)September 5, 2023 | finance.yahoo.comCNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 14, 2023 | finance.yahoo.comCNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming MilestonesAugust 14, 2023 | finance.yahoo.comCNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line TherapyAugust 8, 2023 | benzinga.comCNS Pharma's Lead Drug Candidate Crosses The Blood Brain Barrier - What Does That Mean? Watch the full show here!August 3, 2023 | finance.yahoo.comCNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)August 3, 2023 | finance.yahoo.comCNS Pharmaceuticals to Present at Benzinga's Virtual Biotech ConferenceJuly 28, 2023 | finanznachrichten.deCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer ConferenceJuly 27, 2023 | finance.yahoo.comCNS Pharmaceuticals (NASDAQ:CNSP) Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer ConferenceJuly 21, 2023 | finance.yahoo.comCNSP - CNS Pharmaceuticals, Inc.July 5, 2023 | finance.yahoo.comCNS Pharmaceuticals to Participate in the Virtual Investor Summer Spotlight SeriesJune 14, 2023 | finanznachrichten.deCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-VestJune 14, 2023 | finance.yahoo.comCNS Pharmaceuticals (NASDAQ:CNSP) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-VestMay 25, 2023 | finance.yahoo.comCNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)May 16, 2023 | markets.businessinsider.comMaxim Group Reaffirms Their Hold Rating on CNS Pharmaceuticals (CNSP)May 16, 2023 | marketwatch.comBioMedNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q1 2023 Results, Corporate Update Get CNS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter. Email Address 4 Cryptos BETTER than Bitcoin (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin Click For My #1 FREE Crypto for 2024 CNSP Media Mentions By Week CNSP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CNSP News Sentiment▼0.460.53▲Average Medical News Sentiment CNSP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CNSP Articles This Week▼41▲CNSP Articles Average Week Get CNS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CMND News Today DRMA News Today ATXI News Today CYTO News Today GLMD News Today SLRX News Today SNOA News Today NTBL News Today ALLR News Today ONCO News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CNSP) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceDems have chosen Biden replacement?Paradigm PressThe Next Industry Being Reshaped By AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchShocking $16T Elon Musk Crypto LeakCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlace[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.